Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Stomach Neoplasms 30Carcinoma, Hepatocellular 22Small Cell Lung Carcinoma 15Colorectal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Sarcoma 13Ovarian Neoplasms 12Breast Neoplasms 12Triple Negative Breast Neoplasms 9Nasopharyngeal Carcinoma 9Esophageal Squamous Cell Carcinoma 9Cholangiocarcinoma 9Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Osteosarcoma 6Lung Neoplasms 6Pancreatic Neoplasms 5Head and Neck Neoplasms 5Esophageal Neoplasms 5Uterine Cervical Neoplasms 4Thyroid Neoplasms 4Neoplasms 4Melanoma 4Solid Tumor 3Recurrence 3Neoplasm Metastasis 3Liver Neoplasms 3Glioma 3Gastric Adenocarcinoma 3Carcinoma, Adenoid Cystic 3

Interventions

Imatinib Mesylate 27regorafenib 8nilotinib 6Sunitinib 6pazopanib 3Temozolomide 3Paclitaxel 3Nivolumab 3Ipilimumab 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3trametinib 2spartalizumab 2ripretinib 2ponatinib 2envafolimab 2Specimen Handling 2Sorafenib 2Neoadjuvant Therapy 2Magnetic Resonance Spectroscopy 2Laparoscopy 2Dasatinib 2Carboplatin 2CTLA-4 Antigen 25-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide 2vatalanib 1temsirolimus 1rubitecan 1romidepsin 1perifosine 1pemigatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Stromal Tumors × apatinib × Clear all
NCT05905887 2026-04-07

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Asan Medical Center

Phase 2 Recruiting
48 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡